Topics

NICE draft guidance rules against NHS reimbursement of Roche's Tecentriq for triple-negative breast cancer https://www.firstwordpharma.com/node/1671295  $RHHBY

06:44 EDT 3 Oct 2019 | FirstWord Pharma

NICE draft guidance rules against NHS reimbursement of Roche's Tecentriq for triple-negative breast cancer https://www.firstwordpharma.com/node/1671295 

Original Article: NICE draft guidance rules against NHS reimbursement of Roche's Tecentriq for triple-negative breast cancer https://www.firstwordpharma.com/node/1671295  $RHHBY

NEXT ARTICLE

More From BioPortfolio on "NICE draft guidance rules against NHS reimbursement of Roche's Tecentriq for triple-negative breast cancer https://www.firstwordpharma.com/node/1671295  $RHHBY"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...